Table 1.
Characteristics of Hepather patients included in the external validation of LCR1-LCR2 algorithm.
| Characteristic | Hepather cohort included (n = 4,903) | Missing data |
|---|---|---|
| HCC, n (%) | 214 (4.4) | 0 |
| LCR1-LCR2 algorithm, n (%) | 0 | |
| Low risk | 3,755 (76.6) | |
| High risk | 1,148 (23.4) | |
| Follow-up time, years, median (IQR) | 5.8 (4.2–11.4) | 0 |
| Age at inclusion, years (IQR) | 55.6 (49.0–64.4) | 0 |
| Age at FibroTest™ time, years (IQR) | 52.6 (45.1–61.1) | 0 |
| Men, n (%) | 2,412 (49.2) | 0 |
| Body mass index (kg/m2) | 24.4 (21.9–27.4) | 18 |
| Smoker, n (%) | 4 | |
| At inclusion | 1,689 (34.5) | |
| Previously | 2,985 (61.0) | |
| Geographical origin, n (%) | 39 | |
| France or Eastern Europe | 3,488 (71.7) | |
| Asia | 108 (2.2) | |
| North Africa | 427 (8.8) | |
| Other (mostly Sub-Saharan) | 841 (17.3) | |
| Past excessive alcohol use, n (%) | 1,225 (25.0) | 0 |
| Time since HCV infection, (IQR) | 10.1 (3.3–16.6) | 88 |
| HCV contamination cause, n (%) | 1,598 | |
| Drug usage | 836 (25.3) | |
| Transfusion | 1,094 (33.1) | |
| Other or unknown | 1,375 (41.6) | |
| HCV genotype, n (%) | 24 | |
| 1 | 3,300 (67.6) | |
| 2 | 332 (6.8) | |
| 3 | 547 (11.2) | |
| 4 | 583 (11.9) | |
| 5–7 | 117 (2.4) | |
| Fibrosis at inclusion using Hepather criteria, n (%) | 210 | |
| F0 | 1,271 (27.1) | |
| F1 | 1,055 (22.5) | |
| F2 | 540 (11.5) | |
| F3 | 801 (17.1) | |
| F4 | 1,026 (21.9) | |
| Fibrosis at first FibroTest™ assessment, n (%) | 0 | |
| F0 (≤0.21) | 1,605 (32.7) | |
| F1 (>0.21) | 1,098 (22.4) | |
| F2 (0.48) | 472 (9.6) | |
| F3 (0.58) | 836 (17.1) | |
| F4 (0.74) | 892 (18.2) | |
| Alanine aminotransferase (IU/L) at inclusion (IQR) | 55 (36–90) | 58 |
| Type 2 diabetes mellitus, n (%) | 506 (10.3) | 0 |
| Arterial hypertension, n (%) | 1,313 (26.8) | 1 |
| Alpha-fetoprotein class (ng/ml), n (%) | 728 | |
| <6 | 2,841 (68.0) | |
| 6 to <10 | 654 (15.7) | |
| 10 to <20 | 420 (10.1) | |
| 20 to <120 | 236 (5.6) | |
| >120 | 24 (0.6) | |
| HCV treatment, n (%) | 396 | |
| With sustained virological response | 3,405 (75.5) | |
| Without sustained virological response | 1,102 (24.5) |
HCC, hepatocellular carcinoma; LCR, Liver Cancer Risk.